Literature DB >> 7475932

Pressor response induced by the hippocampal administration of neostigmine is suppressed by M1 muscarinic antagonist.

H Hori1, K Haruta, M Nanki, N Sakamoto, K Uemura, T Matsubara, K Itoh, A Iguchi.   

Abstract

We investigated the roles played by three muscarinic receptors (M1, M2, and M3) in the pressor response with bradycardia that followed the injection of neostigmine (5 x 10(-8) mol) into the hippocampus of anesthetized rats. These changes were blocked by the co-administration of methylatropine (5 x 10(-8) mol). The intrahippocampal injection of pirenzepine (M1 antagonist) (5 x 10(-9) - 5 x 10(-7) mol) suppressed the neostigmine-induced pressor response dose-dependently. However injection of gallamine (M2 antagonist) (5 x 10(-8) - 5 x 10(-7) mol) and of 4-DAMP (M1 and M3 antagonist) (5 x 10(-8) - 5 x 10(-7) mol) did not suppress this hypertensive response. These findings suggest that the neostigmine-induced pressor response with bradycardia is mediated through the M1 muscarinic receptor subtype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7475932     DOI: 10.1016/0024-3205(95)02165-f

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Spontaneously hypertensive rats cholinergic hyper-responsiveness: central and peripheral pharmacological mechanisms.

Authors:  E Lazartigues; C Brefel-Courbon; M A Tran; J L Montastruc; O Rascol
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Central acetylcholinesterase inhibition improves hemodynamic counterregulation to severe blood loss in alcohol-intoxicated rats.

Authors:  Keisa W Mathis; Patricia E Molina
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-06-10       Impact factor: 3.619

3.  Muscarinic cholinergic modulation of synaptic transmission and plasticity in rat hippocampus following chronic lead exposure.

Authors:  Mingliang Tang; Le Luo; Damiao Zhu; Ming Wang; Yunyun Luo; Huili Wang; Di-Yun Ruan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-21       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.